JP Morgan raises target price on Dechra Pharmaceuticals
Analysts at JP Morgan Cazenove raised their target price on veterinary pharmaceuticals group Dechra from 3,200.0p to 3,600.0p on Thursday, stating they expect a year of "strong topline growth" to take place in 2021.
Dechra Pharmaceuticals
3,866.00p
08:01 16/01/24
FTSE 250
20,356.07
14:45 18/11/24
FTSE 350
4,462.29
14:45 18/11/24
FTSE All-Share
4,420.03
14:45 18/11/24
Pharmaceuticals & Biotechnology
19,157.67
14:45 18/11/24
Despite lingering pressures from Covid-19, JP Morgan still sees Dechra delivering 11% revenue growth in the coming year, or 5% on an organic basis, and after also reflecting increased research and development investment and dilution from the company's June equity raise, the analysts still see roughly 5% core earnings per share growth.
Looking beyond 2021, JPM expects organic earnings per share growth to accelerate to "a double-digit" compound annual growth rate for 2022-24, with continued strong topline and margin expansion.
"Our forecasts could also prove conservative for 2021 and beyond, given the recent Covid-19 prompted spike in dog ownership, which could translate into a demand boost for Dechra products," added JPM.
On top of this, the analysts noted that it also sees further potential upside from Dechra putting its now under-geared balance sheet to use.
"With a strong and sustainable organic growth outlook, M&A upside, and diversification from US healthcare reform headwinds, we remain 'overweight'," said JPM.